-
link to article
- by Ethical Skeptic
Summary
Seven of the major eleven International Classification of Diseases codes tracked by the US National Center for Health Statistics exhibit stark increase trends beginning in the first week of April 2021 – featuring exceptional growth more robust than during even the Covid-19 pandemic time frame. This date of inception is no coincidence, in that it also happens to coincide with a key inflection point regarding a specific body-system intervention in most of the US population. These seven pronounced increases in mortality alarmingly persist even now.
The following work is the result of thousands of hours of dynamic data tracking and research on the part of its author. The reader should anticipate herein, a journey which will take them through the methods and metrics which serve to identify this problem, along with a deductive assessment of the candidate causal mechanisms behind it. Alternatives as to cause which include one mechanism in particular, that is embargoed from being allowed as an explanation, nor even mere mention in some forums.
At the end of this process, we will be left with one inescapable conclusion. One which threatens the very fabric and future of health policy in the US for decades to come.
Let's start with the truth!
Support the Broken Science Initiative.
Subscribe today →
recent posts
Metabolic health, medical education, and the case for bringing clinicians and coaches together
At the 2026 Unbreakable Health Retreat in Miami, Emily Kaplan hosted a panel with Bob Kaplan, Professor Thomas Seyfried, and Dr. Derek Lee on what it means to treat cancer as a metabolic disease. They discussed the glucose-ketone index (GKI), nutritional ketosis, and strategies aimed at restricting the fuels cancer cells depend on while considering how metabolic therapy can fit alongside standard cancer treatment.
The conversation also addressed the practical realities patients face when trying to pursue a metabolic approach within the conventional oncology system, including questions about nutrition, repurposed drugs, inherited cancer risk, and how to evaluate different treatment options. Seyfried and Lee connected these clinical questions back to mitochondrial dysfunction, fermentation, and the metabolic vulnerabilities that may offer additional targets for cancer treatment.
An abbreviated version of this discussion is available here, for free.
At the 2026 Unbreakable Health Retreat in Miami, Professor Thomas Seyfried presented the case that cancer is fundamentally a mitochondrial metabolic disease rather than primarily a genetic one. He contrasts the dominant somatic mutation theory with a metabolic model in which impaired mitochondrial respiration drives a shift toward fermentation, dysregulated cell growth, and the mutations commonly associated with cancer.
Citing the work of Otto Warburg and research from his lab at Boston College, Seyfried explains how cancer cells rely heavily on fermentable fuels—particularly glucose and glutamine—and why mitochondrial dysfunction sits upstream of many of the genetic abnormalities seen in tumors. He also discusses reactive oxygen species, altered cellular signaling, and the role of mitochondria in regulating cell growth and behavior.
The presentation then turns to the therapeutic implications of this model. Seyfried explains strategies aimed at placing tumor cells under metabolic stress by restricting the fuels they depend on, including ketogenic metabolic therapy and approaches targeting glucose and glutamine. For Seyfried, the therapeutic target follows directly from the biology: restrict the fuels cancer cells depend on, exploit their metabolic weaknesses, and treat mitochondrial dysfunction as the central feature of the disease.
An abbreviated version of this discussion is available here, for free.
MetFix and BSI Members can view the full 54-minute video.
